Close Menu

CHDI Foundation

Alnylam Pharmaceuticals executives last week disclosed that the company has dropped out of its 50/50 cost- and profit-sharing arrangement with Medtronic for the preclinical RNAi-based Huntington's disease therapy ALN-HTT, opting instead to let its partner incur all expenses assoc

The firm will provide the foundation with structure-based drug discovery services.

Alnylam said that the non-profit CHDI Foundation has agreed to pay up to 50 percent of the costs of advancing a treatment for the disease up through an investigational new drug application filing.

The Galapagos subsidiary will conduct high-content screening and a range of other services for CHDI's Huntington's disease drug development programs.

Pages

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.